Clinical Effect and Mechanism of Modified Danshenyin Against Chronic Atrophic Gastritis with Syndrome of Stasis in Stomach Collateral： Based on Theory of Collateral Diseases
10.13422/j.cnki.syfjx.20221623
- VernacularTitle:基于络病理论观察丹参饮加味治疗慢性萎缩性胃炎胃络瘀阻证的临床疗效及机制
- Author:
Defang WANG
1
;
Ming ZHAO
1
;
Xiaoyi DONG
2
;
Xiaoyan LI
1
Author Information
1. Xining No. 1 People's Hospital， Xining 810000， China
2. Hebei Province Hospital of Traditional Chinese Medicine， Shijiazhuang 050000， China
- Publication Type:Journal Article
- Keywords:
chronic atrophic gastritis;
syndrome of stasis in stomach collateral;
Danshenyin;
collateral disease theory
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(23):122-127
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical effect of Danshenyin on chronic atrophic gastritis and explore the mechanism. MethodA total of 152 patients with chronic atrophic gastritis who were treated in Xining No. 1 People's Hospital were selected and randomized into control group （76 cases） and observation group （76 cases）. The control group was given conventional western medicine treatment， and the observation group was given Danshenyin （oral）. The treatment lasted 8 weeks for both groups. The clinical effect， traditional Chinese medicine （TCM） syndrome score， and pathological score of gastric mucosa were compared between two groups. The content of pepsinogenⅠ （PGⅠ）， pepsinogenⅡ （PGⅡ）， proinflammatory cytokines ［soluble interleukin-2 receptor （sIL-2R）， tumor necrosis factor-α （TNF-α）］， and gastric mucosa-proteting factors ［prostaglandin E2 （PGE2）， calcitonin gene-related peptide （CGRP）］ was determined， and the adverse reactions and recurrence rates were recorded. ResultThe effective rate （91.18%， 62/68） in the observation group was higher than that （7.61%， 52/67） in the control group （χ2=4.727， P<0.05）. The TCM syndrome score in the observation group was lower than that in the control group （P<0.05）. Compared with the control group， the observation group showed low pathological scores of glandular atrophy and intestinal metaplasia and dysplasia （P<0.05）. The observation group had higher serum PGⅠ content and PGⅠ/PGⅡ value and lower PGⅡ content than the control group （P<0.05）. The content of sIL-2R and TNF-α decreased （P<0.05） and that of PGE2 and CGRP increased （P<0.05） in the observation group as compared with those in the control group. The incidence of adverse reactions in the observation group was 7.35% （5/68）， as compared with the 14.93% （10/67） in the control group. The recurrence rates in the 6-month and 12-month follow-up in the observation group were lower than those in the control group， but the difference was not statistically significant （Fisher's exact test）. ConclusionDanshenyin shows satisfactory effect in relieving TCM syndrome， regulating PG secretion， and improving gastric mucosal lesions in the treatment of chronic atrophic gastritis. The mechanism is the likelihood that it modulates sIL-2R， TNF-α， PGE2， and CGRP to alleviate inflammatory damage of gastric mucosa and protect gastric mucosa. The medicine is safe and reduces the recurrence of chronic atrophic gastritis.
